Frontier drug discovery programs require frontier capabilities.
Joshua Meier
Visit on X@joshim57.8K followers
82,516 views
Frontier drug discovery programs require frontier capabilities. Today, we’re excited to share that BMS will be using Chai’s models to support the discovery of new therapeutics. Since rolling out Chai-3 to partners at the start of this year, we’ve partnered with Eli Lilly and Company, Novartis, Pfizer Inc., argenx, and now Bristol Myers Squibb. Many of the world’s leading biopharma companies are now using our models to go after diseases.
Scientific discovery is the domain where access to frontier AI matters the most. At Chai Discovery, we’ve seen first hand how our latest model generations can make the difference between discovering a molecule and not. We’re excited to work with Bristol Myers Squibb to break new ground in medicine and science.
Comments
Comments from the original post on X (Twitter)
No comments yet
